ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

4 links0 made here, not in the record10 judgments3 judges (the rules as one: Rule based)1 record change seen1 read an older version
Claude Opus 5.5Model not recordedRule basedRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05394103Highly Selective CDK7Inhibitor Q901 in SelectedAdvanced Solid TumorsQurient Co., Ltd.Phase 1/Phase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 9 · ClinicalTrials.gov record · Version of 2026-11-09Nov 9 · Rule based · Reading set asideNov 16 · Rule based · Read againRead againCONDITIONSNeoplasm MetastasisThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseAs of now · Rule based · Main conditionMain conditionDRUGSPembrolizumabEntry “KEYTRUDA® (pembrolizumab)”, re…›Nov 1 · A model not recorded · BackgroundNov 16 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerFulvestrantIntervention entry›Nov 16 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerMocaciclibIntervention entry›Nov 1 · A model not recorded · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Pembrolizumab

From the registry record3 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “KEYTRUDA® (pembrolizumab)”the record gives no role
→judged=agrees=agrees
How the 3 judgments split100%of judgments with a known value say Background · partner
Background · 3

All judgments on this study

WhenLinkJudgeDecisionState
Nov 1PembrolizumabA model not recordedBackgroundReplaced
Nov 1MocaciclibA model not recordedTestedRead an older version
Nov 9The record itselfClinicalTrials.gov recordVersion of 2026-11-09Record change
Nov 9The record itselfRule based · nightly checkReading set asideCurrent
Nov 14Neoplasm MetastasisRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 16The record itselfRule based · nightly checkRead againCurrent
Nov 16PembrolizumabClaude Opus 5.5Background · partnerCurrent
Nov 16FulvestrantClaude Opus 5.5Background · partnerCurrent
Nov 18PembrolizumabRule based · role ruleBackgroundAgrees
Nov 18FulvestrantRule based · role ruleBackgroundAgrees
As of nowNeoplasm MetastasisRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.

When a study changes after it was read

Every night, studies whose record changed are compared with the last reading. A change to sites or dates leaves the reading as it is; a reworded entry keeps it; a change to the treatments or conditions marks it to be read again.

Until it is read again, the page shows the last reading and says so.